



Department
of Hemato-Oncology
University Hospital
Olomouc



Faculty of Medicine
and Dentistry


Palacký University
Olomouc

Detection of recurrent somatic variants in cell-free DNA as a tool for disease monitoring in Hodgkin lymphoma

Mgr. Jan Grohmann


Current state of HL

- Up to 80 % pts can be cured; 20 – 30 % progression or relapsed
- PET/CT scan – evaluation for treatment response
 - False positive/false negative results → **looking for new approaches**



Current state of HL

- Up to 80 % pts can be cured; 20 – 30 % progression or relapsed
- PET/CT scan – evaluation for treatment response
 - False positive/false negative results → **looking for new approaches**



Camus et Jardin., *Pharmaceuticals* (2021) **14**, 207.

Liquid biopsy



- Hodgkin genotyping
- Minimal residual disease monitoring (MRD)

NGS approach

- *Target enrichment panel*
 - *B2M, CD36, CIITA, GNA13, HIST1H1E, ITPKB, NFKBIE, PTPN1, SOCS1, SPEN, STAT6, TNFAIP3 and XPO1*
 - Based on Spina *et al.*, 2018 and Camus *et al.*, 2021
- *Library*
 - *SureSelect XT HS2 technology (Agilent Technologies) – target enrichment with molecular barcodes*
 - Input to library preparation - **min. 40 – 50 ng of cfDNA**
- *Sequencing*
 - *NovaSeq6000 (Illumina) - requirement for high coverage – 5000x*
 - *SureCall software (Agilent Technologies) – VAF* = 0.5 %*

NGS approach


101 pts (94 dg., 7 relapse)



58 pts (54 dg., 4 relapse)
Sufficient cfDNA
More than 40 ng
68 % pts Ann arbor stage III – IV
↓
NGS


39 pts (36 dg., 3 relapse)
Insufficient cfDNA
Less than 40 ng
13 % pts Ann arbor stage III – IV
or
Failed library prep. (4 pts/dg.)

Markers for MRD testing revealed by NGS



Up to 40 % of all cHL (27.7 %)

Spina *et al.*, *Blood* (2018); **131** (22): 2413–2425;
Camus *et al.*, *Haematologica*. (2021);**106** (1):154–162






10 - 20 % of all cHL (13.8 %)

Camus *et al.*, *Haematologica* (2016); **101**: 1094-1101.;
Spina *et al.*, *Blood* (2018); **131** (22): 2413–2425


dPCR approach

- *QIAcuity™ probe PCR kit + nanoplate QIAcuity Nanoplate 26K 24-well (Qiagen)*
- Locked nucleic acid probes (LNA probes)
 - reduction of false positivity rates → better sensitivity




MRD monitoring

- *STAT6*, *XPO1* – hotspots
 - Sensitivity up to – 0.1 %
- 6 pts with *XPO1* mutation p.E571K
- 12 pts with *STAT6* mutations
 - 8 pts p.N417Y
 - 1 pt p.G416R
 - 1 pt p.D419N
 - 1 pt p.N421K
 - 1 pt double mutant p.N417D + p.D419A



Negative control *STAT6* N417Y– only WT
Donor cfDNA





Positive control *STAT6* N417Y
0.1 picogram of gBlock with donor cfDNA

MRD monitoring


- *STAT6, XPO1* – hot spots – Sensitivity up to – 0,1 %
- 6 pts with *XPO1* mutation p.E571K → 1 pt early relapse
- 12 pts with *STAT6* mutations
 - 8 pts p.N417Y → 2 pts early relapse
 - 1 pt p.G416R 1 pt primary refractory
 - 1 pt p.D419N
 - 1 pt p.N421K
 - 1 pt double mutant p.N417D + p.D419A

MRD monitoring in patient with *STAT6* p.N417Y mutation using dPCR






STAT6 p.N417Y
 at the time of diagnosis, VAF = 0,76 % (NGS = 1,76 %)




STAT6 p.N417Y
 After first line of chemotherapy, VAF = 0,12 %

NGS/dPCR comparison?



NGS/dPCR comparison?




Dg. *STAT6* N417Y

NGS: 3,47 % VAF

Input NGS: 59,4 cfDNA

dPCR: 3,70 % VAF

Input dPCR: 33,0 ng cfDNA



Relapse *STAT6* N417Y

NGS: negative

Input NGS: 41,5 ng cfDNA

dPCR: 0,33 % VAF

Input dPCR: 27,0 ng cfDNA

Summary

- NGS – screening at the time of diagnosis
- Digital PCR – MRD monitoring in case of presence of molecular marker

Plasma Cell-Free DNA		
Characteristics	Advantages	Disadvantages
<ul style="list-style-type: none"> • Droplet digital PCR 	<ul style="list-style-type: none"> • Short turnaround time • Low cost • Detection of “hotspot” targetable activating mutations • Easy serial testing • 10^{-5} detection limit 	<ul style="list-style-type: none"> • Not commercially available • Insufficient data to verify the reproducibility • False-positive and detection limit concerns
<ul style="list-style-type: none"> • Panel-directed Next-Generation Sequencing (CAPP-seq and other targeted panels) 	<ul style="list-style-type: none"> • Measure disease burden, detect early relapse before radiological progression • Monitor variants’ clearance in chemo sensitive patients versus non-responders patients who display persistent genetic alterations in plasma after treatment 	<ul style="list-style-type: none"> • No standardized technique • Not commercially available • high cost due to elevated number of genes included in the panel • Need trained research teams with experienced bioinformaticians able to combine barcoding and unique molecular identifiers (UMIs) with integrated digital error suppression



Department
of Hemato-Oncology
University Hospital
Olomouc



Faculty of Medicine
and Dentistry

Palacký University
Olomouc

Thank you for your attention

Future goals

- 39 pts with insufficient amount of cfDNA → multiplex dPCR
- redesign of the NGS panel (new NGS/dPCR targets?)